Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer

• Published in: The oncologist (Dayton, Ohio) Ohio), 2022-12, Vol.27 (12), p.1004-e926
• Main Authors: Johnson, Faye M, Janku, Filip, Gouda, Mohamed A, Tran, Hai T, Kawedia, Jitesh D, Schmitz, Debora, Streefkerk, Hendrik, Lee, J Jack, Andersen, Clark R, Deng, Defeng, Rawal, Seema, Shah, Pooja A, El-Naggar, Adel K, Johnson, Jason M, Frederick, Mitchell J
• Format: Article
• Language: English
• Subjects: Apoptosis; Care and treatment; Clinical Trial Results; Diagnosis; Gene mutations; Genetic aspects; Head and neck cancer; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - genetics; Health aspects; Humans; Phosphatidylinositol 3-Kinase; Phosphatidylinositols; Receptor, Notch1 - genetics
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1093/oncolo/oyac185

PI3K/mTOR inhibition leads to apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma (HNSCC) cells. We tested the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant HNSCC. Patients with recurrent/metastatic NOTCH1-mutant HNSCC who had progressed during chemotherapy and immunotherapy received bimiralisib until unacceptable toxicity or progression. To assess whether NOTCH1 mutations can be detected in blood, we measured circulating tumor DNA (ctDNA). To assess activated NOTCH1 protein levels, we quantitated cleaved NOTCH1 (cl-NOTCH) by immunohistochemistry. Eight patients were treated, and 6 were evaluable for response. The objective response rate was 17%. For all 8 patients, median progression-free and overall survival was 5 and 7 months, respectively. Bimiralisib was well tolerated, with expected hyperglycemia. Pharmacokinetic values were consistent with published studies. NOTCH1 mutations were detected in 83.3% of ctDNA. Staining for tumor cl-NOTCH1 was negative. The trial closed early due to sponsor insolvency. Although the trial was small, outcomes with bimiralisib were better than the historical standard of care; Results will need to be confirmed in a larger trial. The lack of cl-NOTCH1 was consistent with loss-of-function mutations and validated our mutation function algorithm. The ability to detect NOTCH1 mutations in blood will help future studies. (ClinicalTrials.gov Identifier: NCT03740100).